top of page

NDR funds novel work in ALS research

Dr. Chandler Walker and his team at the Department of Biomedical Sciences and Comprehensive Care at Indiana University School of Dentistry reported that bisperoxovanadium promotes motor neuron survival and neuromuscular innervation in ALS mouse and cell models in the journal Molecular Brain, micro report.

What is important about this work is that results show the mechanism of action of the protective effects of the therapy. The study is the first to demonstrate the therapeutic effects of these compounds.

While there is more work to do in mouse models, laying the scientific foundation of a primary mechanism of action through inhibition of phosphatase activity (PTEN) and subsequent upregulation of downstream (PI3K/Akt) signaling opens the door to new research. Compounds that target these pathways could eventually lead to new treatments.

NDR is pleased to be a part of this important work by funding basic research in ALS and we thank the Walker team for the acknowledgment.

17 views0 comments

Recent Posts

See All

TVALA Drug Trial

We are happy to announce the first patients are being screened for entry into the clinical trial for our drug TVALA! This Phase 1 study will wrap up in a few months and the Phase 2 will start, it will

Thymosin in the treatment of lung cancer

A new paper authored by Liu and Lu in the Frontiers in Immunology reports the Mechanism and clinical application of thymosin in the treatment of lung cancer. Thymosin is a mixture of peptides obtained


We are hopeful that TVALA will reduce p53 expression in people with ALS. There are two recent publications that give us hope. The first paper is by Maor-Nof et. al. (2022), found in Cell. The found


Les commentaires ont été désactivés.
bottom of page